• About us
    • Profile
    • Board of Directors
    • Research Leadership
  • Our Science
    • Strategy
    • Activities and Technologies
    • Publications
  • Pipeline
    • Pipeline
    • 68Ga-OncoFAP (Imaging)
    • 18F-OncoFAP (Imaging)
    • 177Lu-OncoFAP-23 (Therapy)
    • OncoFAP-GlyPro-MMAE (Therapy)
    • 68Ga-OncoACP3 (Imaging)
    • 18F-OncoACP3 (Imaging)
    • 177Lu-OncoACP3 (Therapy)
    • 225Ac-OncoACP3 (Therapy)
    • 68Ga-OncoCAIX (Imaging)
    • 177Lu-OncoCAIX (Therapy)
  • Press Release & Media
    • Press Releases
    • Events
    • Media Library
  • Work with us
    • Careers
    • Industrial Ph.D. Program
    • Partnering & Fee-For-Services
  • About us
    • Profile
    • Board of Directors
    • Research Leadership
  • Our Science
    • Strategy
    • Activities and Technologies
    • Publications
  • Pipeline
    • Pipeline
    • 68Ga-OncoFAP (Imaging)
    • 18F-OncoFAP (Imaging)
    • 177Lu-OncoFAP-23 (Therapy)
    • OncoFAP-GlyPro-MMAE (Therapy)
    • 68Ga-OncoACP3 (Imaging)
    • 18F-OncoACP3 (Imaging)
    • 177Lu-OncoACP3 (Therapy)
    • 225Ac-OncoACP3 (Therapy)
    • 68Ga-OncoCAIX (Imaging)
    • 177Lu-OncoCAIX (Therapy)
  • Press Release & Media
    • Press Releases
    • Events
    • Media Library
  • Work with us
    • Careers
    • Industrial Ph.D. Program
    • Partnering & Fee-For-Services

Dario Neri and his lab at the ETH Zurich are the recipient of an ERC Advanced Grant for the project titled “Zauberkugel: fulfilling Paul Ehrlich’s dream of therapeutics with activity on demand”. Zurich (Switzerland) June 1, 2015.

by last | Jun 1, 2015 | 2015, Press Releases

Giulio Casi presented “Targeting disease with armed antibodies and small molecule drug conjugates.” at SMI ADC Summit 2015. London (UK), 18th-19th May, 2015.

by last | May 22, 2015 | 2015, Press Releases

Dario Neri presented “Arming tumor-targeting antibodies with cytokine payloads: Emerging clinical results.” at PEGS (Essential Protein Engineering Summit) 2015. Boston (USA), 4th-8th May, 2015.

by last | May 1, 2015 | 2015, Press Releases

Dario Neri presented “Arming tumor-targeting antibodies with cytokine payloads: Emerging clinical results.” at AACR Annual Meeting 2015. Philadelphia (USA), 19th-22nd April, 2015

by last | Apr 19, 2015 | 2015, Press Releases

Mattia Matasci presented “Targeting disease with armed antibodies small molecule drug conjugates” at Antibody Targeted-drug conjugates 2015. Porto (Portugal), 13th-15th April, 2015.

by last | Apr 13, 2015 | 2015, Press Releases

Dario Neri presented “Antibody-cytokine fusion proteins

by last | Mar 17, 2015 | 2015, Press Releases

Dario Neri presented “Antibody-cytokine fusion proteins: from the bench to the clinic” at 1st International Symposium for Medicinal Sciences organized by the Pharmaceutical Society of Japan (PSJ) in association with the 135th Annual Meeting of the PSJ...
« Older Entries
Next Entries »

Recent Posts

  • 2026 Swiss Chemical Society (SCS) Industrial Science Award for Samuele Cazzamalli, Head of Research at Philochem
  • Philochem to attend the Festival of Biologics 2025 in Basel on September 30-October 2, 2025
  • Philochem AG Announces Completion of Antitrust Clearance and Closing of the OncoACP3 Licensing Agreement with RayzeBio, a Bristol Myers Squibb Company, With a Potential Value of up to $1.35 Billion Plus Royalties
  • Philogen is pleased to invite you to a webinar with Prof. Dario Neri, taking place today, June 11, at 11:00 ET | 17:00 CET.
  • Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties.
Privacy Policy / Cookie Policy

Contacts

  • Follow

Philochem AG | Libernstrasse 3 | CH-8112 | Otelfingen – Switzerand |MWST-Nr/VAT-REG: CHE-113.181.443 | Registration Nr. CH-020.3.030.226-7 Ph. (+41) 43 544 88 00 | Fax (+41) 43 544 88 09| info@philochem.ch